Medigene (MDG1) Q3 2024 earnings summary

Executive summary

• Advanced TCR-T therapy pipeline, including MDG1015 and MDG2021, with regulatory milestones achieved in the US and Europe.

• Entered a strategic partnership with WuXi Biologics to co-develop TCR-guided T cell engagers for solid tumors.

• Presented new UniTope & TraCR technology at major scientific conferences, enhancing TCR identification and monitoring.

• Expanded intellectual property portfolio to 29 patent families, with new patents granted in China, Europe, and Hong Kong.

• Completed a 2:1 share consolidation, reducing shares outstanding and reclassifying capital to reserves.

Financial highlights

• Q3 2024 revenue was EUR 1.4 million, down from EUR 1.6 million in Q3 2023; 9-month 2024 revenue totaled EUR 5.9 million.

• R&D expenses for Q3 2024 were EUR 2.7 million, down from EUR 3.2 million year-over-year; 9-month R&D spend was EUR 8.9 million.

• Cash and cash equivalents stood at EUR 9.5 million as of September 30, 2024 (EUR 16.7 million at December 31, 2023).

Outlook and guidance

• Cash runway extended into July 2025 following a successful capital raise and share consolidation.

• 2024 revenue guidance maintained at EUR 9.0–11.0 million, with R&D costs expected to be EUR 11.5–13.5 million.

• Guidance includes likely milestone payments from existing partnerships but excludes potential new deals.

• Ongoing efforts to secure additional financing to extend runway into 2026 and beyond.